Abstract
Endometrial cancer arises from the uterine body and fundus in many cases, but can also originate from the lower region of the uterine body through the upper region of the cervix. Such tumors are referred to as carcinoma of the lower uterine segment (LUS) or isthmus, and account for 3-6.3% of all cases of endometrial cancer. This relatively low incidence has permitted performance of only small-scale studies, but the clinical and pathological characteristics of carcinoma of the LUS in all these reports have differed from those of other endometrial cancers. Generally, endometrial cancer is classified into estrogen-dependent endometrioid adenocarcinoma (designated as type I), and non-endometrioid types that are less associated with estrogen and include poorly differentiated adenocarcinoma (type II). In some reports, carcinoma of the LUS has been found to have type II characteristics. Carcinoma of the LUS has also been associated with Lynch syndrome, a hereditary disease with frequent development of colorectal, endometrial, and ovarian cancers. Lynch syndrome is thought to be induced by mismatch repair gene mutation. The frequency of Lynch syndrome in cases of general endometrial cancer is 1-2%. In contrast, the frequency in patients with carcinoma of the LUS is much higher, with up to 29% of cases diagnosable with Lynch syndrome and a high frequency of hMSH2 mutation found in one study. This suggests that further investigation of the clinical and pathological characteristics of carcinoma of the LUS and the association with Lynch syndrome is required through performance of a large-scale survey.
Keywords: Endometrial cancer, lower uterine segment, Lynch syndrome, DNA mismatch repair gene, hMSH2, nulliparity, infertility, polycystic ovary syndrome, adenocarcinoma, amenorrhea
Current Genomics
Title: Carcinoma of the Lower Uterine Segment (LUS): Clinicopathological Characteristics and Association with Lynch Syndrome
Volume: 12 Issue: 1
Author(s): Kenta Masuda, Kouji Banno, Megumi Yanokura, Yusuke Kobayashi, Iori Kisu, Arisa Ueki, Asuka Ono, Hiroyuki Nomura, Akira Hirasawa, Nobuyuki Susumu and Daisuke Aoki
Affiliation:
Keywords: Endometrial cancer, lower uterine segment, Lynch syndrome, DNA mismatch repair gene, hMSH2, nulliparity, infertility, polycystic ovary syndrome, adenocarcinoma, amenorrhea
Abstract: Endometrial cancer arises from the uterine body and fundus in many cases, but can also originate from the lower region of the uterine body through the upper region of the cervix. Such tumors are referred to as carcinoma of the lower uterine segment (LUS) or isthmus, and account for 3-6.3% of all cases of endometrial cancer. This relatively low incidence has permitted performance of only small-scale studies, but the clinical and pathological characteristics of carcinoma of the LUS in all these reports have differed from those of other endometrial cancers. Generally, endometrial cancer is classified into estrogen-dependent endometrioid adenocarcinoma (designated as type I), and non-endometrioid types that are less associated with estrogen and include poorly differentiated adenocarcinoma (type II). In some reports, carcinoma of the LUS has been found to have type II characteristics. Carcinoma of the LUS has also been associated with Lynch syndrome, a hereditary disease with frequent development of colorectal, endometrial, and ovarian cancers. Lynch syndrome is thought to be induced by mismatch repair gene mutation. The frequency of Lynch syndrome in cases of general endometrial cancer is 1-2%. In contrast, the frequency in patients with carcinoma of the LUS is much higher, with up to 29% of cases diagnosable with Lynch syndrome and a high frequency of hMSH2 mutation found in one study. This suggests that further investigation of the clinical and pathological characteristics of carcinoma of the LUS and the association with Lynch syndrome is required through performance of a large-scale survey.
Export Options
About this article
Cite this article as:
Masuda Kenta, Banno Kouji, Yanokura Megumi, Kobayashi Yusuke, Kisu Iori, Ueki Arisa, Ono Asuka, Nomura Hiroyuki, Hirasawa Akira, Susumu Nobuyuki and Aoki Daisuke, Carcinoma of the Lower Uterine Segment (LUS): Clinicopathological Characteristics and Association with Lynch Syndrome, Current Genomics 2011; 12 (1) . https://dx.doi.org/10.2174/138920211794520169
DOI https://dx.doi.org/10.2174/138920211794520169 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
New insights on Pediatric Tumors and Associated Cancer Predisposition Syndromes
Because of the broad spectrum of children cancer susceptibility, the diagnosis of cancer risk syndromes in children is rarely used in direct cancer treatment. The field of pediatric cancer genetics and genomics will only continue to expand as a result of increasing use of genetic testing tools. It's possible that ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacogenetics of Estrogen Metabolism and Transport in Relation to Cancer
Current Drug Metabolism Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer
Current Medicinal Chemistry Intra- and Interdomain Flexibility in Matrix Metalloproteinases: Functional Aspects and Drug Design
Current Pharmaceutical Design From 2D to 3D - a New Dimension for Modelling the Effect of Natural Products on Human Tissue
Current Pharmaceutical Design Prediction and Monitoring of Therapeutic Response by Molecular Imaging
Current Medical Imaging Antineoplastic Activity of an Old Natural Antidiabetic Biguanide on the Human Thyroid Carcinoma Cell Line
Anti-Cancer Agents in Medicinal Chemistry Epigenetic Mechanism Involved in the HBV/HCV-Related Hepatocellular Carcinoma Tumorigenesis
Current Pharmaceutical Design Toward The Rational Design of Cell Fate Modifiers Notch Signaling as a Target for Novel Biopharmaceuticals
Current Pharmaceutical Biotechnology Kinase Phosphorylation-based Mechanisms of PARP Inhibitor Resistance During Synthetic Lethal Oncotherapy
Current Signal Transduction Therapy Indoleamine 2,3-dioxygenase, Tregs and Cancer
Current Medicinal Chemistry From French Paradox to Cancer Treatment: Anti-cancer Activities and Mechanisms of Resveratrol
Anti-Cancer Agents in Medicinal Chemistry Inhibiting the Enzymes of the Endothelin and Renin-Angiotensin Systems in Cancer
Current Enzyme Inhibition Prediction and Identification of Krüppel-Like Transcription Factors by Machine Learning Method
Combinatorial Chemistry & High Throughput Screening Understanding the Monoclonal Antibody Involvement in Targeting the Activation of Tumor Suppressor Genes
Current Topics in Medicinal Chemistry Characterization of Plant-Bacterial Interactions Using Proteomic Approaches
Current Proteomics Angiogenesis-Related Cytokines in Rheumatoid Arthritis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Fibroblast Growth Factor-2, Bone Homeostasis and Fracture Repair
Current Pharmaceutical Design Defining the Role of Integrin αvβ6 in Cancer
Current Drug Targets Cancer Stem Cells: A New Paradigm for Understanding Tumor Growth and Progression and Drug Resistance
Current Medicinal Chemistry Phytoconstituents of <i>Lantana camara</i> L.: Rekindling Hope in the Cancer Treatment
Current Bioactive Compounds